Diclof S.R 100
Diclof S.R 100
- It inhibits prostaglandin biosynthesis which plays a major role in causing inflammation, pain and fever. Medication with Diclofenac sodium can relieve the symptoms of inflammation, but can not cure the cause. In rheumatic diseases, Diclofenac sodium elicits a clinical response characterized by marked relief from signs and symptoms such as pain at rest, pain on movement, morning stiffness, and swelling of the joints, as well as by an improvement in function.
- Diclofenac is almost completely absorbed. Food has no clinical relevant influence on the absorption and bioavailability of Diclofenac.
- No accumulation occurs provided the recommended dosage intervals are observed even in patients suffering from renal impairment. 99.7% of Diclofenac is bound to serum proteins. It enters the synovial fluid, and reaches higher levels in the synovial fluid than in the plasma and remain higher for up to 12 hours.
- Diclofenac is subject to first-pass metabolism and then excreted mainly in the urine (about 65%) but also in the bile (about 35%).
Indication
Dosage & Administration
- The dose should be adjusted to the patient’s response, tolerance and severity of symptoms.
- DICLOF ® capsules or tablets should be swallowed whole with plenty of liquid preferably during or after meals.
Adults:
The recommended daily dosage is 75 -150 mg as the following:
- One capsule of DICLOF ® SR 100 per day during long term treatment.
- Or 1 -3 enteric coated tablets of 25 mg or 50 mg/day in 2- 3 divided doses
- In primary dysmenorrhoea the daily dosage should be individually adjusted and generally 50-150 mg.
Children:
- The initial dose for children aged 6 years and over: 2-3 mg per Kg body weight / day, in 2 - 3 divided doses.
- The dose range is between 0.5-2 mg/Kg body weight daily, according to the severity of the case.
- In case of juvenile rheumatoid arthritis, the dose can be increased to 3 mg/Kg body weight daily on 2-3 divided doses.
- DICLOF ®should not be given to children under 12 months of age.
- Or as directed by physician
- Owing to the possibility of uterine inertia and/or premature closure of the ductus arteriosus, DICLOF ® should not be used in the third trimester.
- DICLOF ® passes into breast milk, but in quantities so small to be harmful to a breast-fed infant